Understand the source comparison
Can You Take VIP Daily: Protocol Comparison
Choosing the right VIP dosing frequency depends on your research endpoint, target tissue, and study duration. This table compares daily, intermittent, and twice-daily protocols across key variables. Daily (once/day) 10–50 nmol/kg SC/IP Moderate after 14+ days
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Choosing the right VIP dosing frequency depends on your research endpoint, target tissue, and study duration. This table compares daily, intermittent, and twice-daily protocols across key variables.
- Daily (once/day)
- 10–50 nmol/kg SC/IP
- Moderate after 14+ days
- Chronic inflammation, autoimmune models, sustained immunomodulation
- Aliquot for 7-day intervals, refrigerate at 2–8°C, freeze remainder
- Standard for sustained effect studies; incorporate washout intervals beyond 2 weeks to preserve receptor sensitivity
- Intermittent (every other day or 3×/week)
- 15–60 nmol/kg SC/IP
- Low
- Acute intervention, receptor sensitivity preservation, dose-response studies
- Same as daily, but lower total peptide consumption
- Preferred when measuring peak response or avoiding desensitization. Less common in chronic disease models
- Twice-daily (AM/PM)
- 5–25 nmol/kg per dose
- High if continuous for >7 days
- Circadian regulation, biphasic signaling, CNS-targeted endpoints
- Requires fresh aliquot preparation every 3–4 days due to higher usage rate
- Use only when biological rationale supports biphasic dosing; risk of rapid receptor downregulation without rest intervals
- Continuous infusion (osmotic pump)
- 1–10 nmol/kg/hour
- Very high; expect 30–50% receptor loss by 48 hours
- Acute ischemia, sepsis models, studies <72 hours duration
- Prefilled pump must be prepared <24 hours before implantation; VIP degrades in pump reservoir
- Avoid for studies >3 days unless receptor downregulation itself is the endpoint being studied
- Daily VIP administration balances practical feasibility with sustained biological effect for most inflammatory and immune modulation studies. Twice-daily dosing adds logistical complexity and accelerates receptor desensitization unless justified by circadian or biphasic endpoints. Continuous infusion is reserved for acute studies where plasma VIP concentration must remain elevated throughout the observation window. But receptor density collapses rapidly under these conditions.